Join us for an exclusive presentation with the CEO of Vixiar Medical, a life science innovator targeting the $1.5B Congestive Heart Failure (CHF) market.
Vixiar offers a non-invasive, cost-effective solution designed to improve patient outcomes and significantly cut hospital readmissions for over 6 million CHF patients. With near-term FDA clearance, a clear path to scale, and a targeted acquisition exit by 2027, Vixiar represents a high-impact investment opportunity.
